Skip to main content
. Author manuscript; available in PMC: 2017 Apr 25.
Published in final edited form as: J Med Chem. 2009 Jan 8;52(1):74–86. doi: 10.1021/jm800937p

Table 4.

Toxicologic Evaluation of 16aa

parameter units control 3 mg/kg 16a 10 mg/kg 16a 50 mg/kg 16a
white blood cells 109/L 3.55–9.83 3.73–7.99 4.95–7.03 3.65–7.1
lymphocytes 109/L 3.44–8.88 3.61–6.78 3.94–5.84 3.5–5.62
monocytes 109/L 0.04–0.36 0.11–0.34 0.08–0.28 0.04–0.35
granulocytes 109/L 0.06–0.36 0.01–0.91 0.61–0.93 0.08–1.13
red blood cells 1012/L 10.37–11.76 10.37–11.33 9.22–10.93 8.99–10.98
hemoglobin g/dL 13.2–14 12.8–14 11.7–14.1 12.2–13.5
albumin g/dL 3.2–3.4 3.3–3.4 2.9–3.4 2.6–3.1
alkaline phosphatase U/L 87–134 85–127 85–113 80–86
alanine aminotransferase U/L 47–87 40–134 44–46 37–52
amylase U/L 926–981 878–1206 816–1054 760–967
blood urea nitrogen mg/dL 15–19 17–19 11–16 14–22
phosphate mg/dL 5.7–9.5 5.1–5.6 5.7–6.2 5.5–8.1
creatinine mMg/dL 0.2–0.3 0.2–0.4 0.2–0.3 0.2–0.3
Na+ mmol/L 150–155 150–155 144–151 145–153
K+ mmol/L 7.7–7.9 7.3–7.5 7.2–8.2 6.3–6.7
glucose mg/dL 70–94 80–90 87–129 136–163
a

The indicated doses of compound 16a were administered by intraperitoneal injection daily for 7 days and blood was collected after an additional 7 days of observation. The ranges of values for cell counts and blood chemistry are given.

HHS Vulnerability Disclosure